Health and Fitness Health and Fitness
Tue, May 1, 2012
Mon, April 30, 2012
[ Mon, Apr 30th 2012 ] - Market Wire
Hologic to Acquire Gen-Probe
Sun, April 29, 2012
Sat, April 28, 2012
Fri, April 27, 2012
Thu, April 26, 2012
Wed, April 25, 2012
Tue, April 24, 2012
Mon, April 23, 2012
Sun, April 22, 2012
Sat, April 21, 2012
Fri, April 20, 2012
Thu, April 19, 2012
Wed, April 18, 2012
[ Wed, Apr 18th 2012 ] - Market Wire
00 a.m. ET

ARIAD to Webcast Conference Call on First Quarter 2012 Financial Results


//health-fitness.news-articles.net/content/2012/ .. all-on-first-quarter-2012-financial-results.html
Published in Health and Fitness on Wednesday, April 25th 2012 at 4:57 GMT by Market Wire   Print publication without navigation


CAMBRIDGE, Mass.--([ ])--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Wednesday, May 9, 2012. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. ARIAD senior management will discuss the Companyas financial results as of March, 31, 2012, as well as key corporate objectives and additional corporate activities. The Company will announce highlights of these topics in a press release to be issued before the market opens on May 9, 2012 prior to the conference call.

The live webcast can be accessed by visiting the investor relations section of the Company's website at [ http://investor.ariad.com ]. The call can be accessed by dialing 800-260-8140 (domestic) or 617 -614-3672 (international) five minutes prior to the start time and providing the pass code 33704570. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIADas approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit [ http://www.ariad.com ] or follow ARIAD on [ Twitter ].


Publication Contributing Sources